Estamos no ar no ! Saiba mais
ícone de MMSI

Merit Medical Systems

89,20 USD
-0,37
0,41%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
89,20
0,00
0%
1 dia
-0,41%
5 dias
1,77%
1 mês
3,55%
3 meses
18,07%
6 meses
27,25%
No acumulado do ano
3,18%
1 ano
10,38%
5 anos
28,88%
10 anos
277,97%
 

Sobre: Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.

Funcionários: 7.500

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 51,9%
Neutro 44,4%
Negativo 3,7%
Positivo
Zacks Investment Research
há 7 dias
Cancer Stocks to Consider as Oncology Innovation Accelerates
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
Cancer Stocks to Consider as Oncology Innovation Accelerates
Neutro
GlobeNewsWire
há 10 dias
Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026
SOUTH JORDAN, Utah, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2026, after the close of the stock market on Thursday, October 29, 2026. Merit plans to hold its investor conference call on the same day (Thursday, October 29, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific).
Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026
Neutro
Zacks Investment Research
há 10 dias
HSIC or MMSI: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Henry Schein (HSIC) or Merit Medical (MMSI). But which of these two stocks presents investors with the better value opportunity right now?
HSIC or MMSI: Which Is the Better Value Stock Right Now?
Neutro
Zacks Investment Research
há 10 dias
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's broad product portfolio, global expansion and strategic M&A support growth, while tariffs and China pressures remain key risks.
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
Positivo
Zacks Investment Research
há 15 dias
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve
Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve
Neutro
GlobeNewsWire
mês passado
Merit Medical to Participate in Upcoming Investors Conferences in September
SOUTH JORDAN, Utah, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management is scheduled to participate in the following upcoming investor conferences:
Merit Medical to Participate in Upcoming Investors Conferences in September
Neutro
Zacks Investment Research
mês passado
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
Neutro
Zacks Investment Research
mês passado
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Positivo
Zacks Investment Research
mês passado
Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
Merit Medical's growth case is strengthening as launches, acquisitions and therapeutic products broaden its mix, but its premium valuation raises the execution bar.
Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
Positivo
Zacks Investment Research
mês passado
Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?
Merit Medical's 22.2% monthly rally gains support from stronger Q2 growth and a raised 2026 outlook, but valuation and tariff risks remain.
Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?
Gráficos de preços implementados com Lightweight Charts™